JP2025175052A5 - - Google Patents

Info

Publication number
JP2025175052A5
JP2025175052A5 JP2025147778A JP2025147778A JP2025175052A5 JP 2025175052 A5 JP2025175052 A5 JP 2025175052A5 JP 2025147778 A JP2025147778 A JP 2025147778A JP 2025147778 A JP2025147778 A JP 2025147778A JP 2025175052 A5 JP2025175052 A5 JP 2025175052A5
Authority
JP
Japan
Prior art keywords
lnp
tissue
cells
substituted
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025147778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025175052A (ja
Filing date
Publication date
Priority claimed from JP2022523023A external-priority patent/JP7744687B2/ja
Application filed filed Critical
Publication of JP2025175052A publication Critical patent/JP2025175052A/ja
Publication of JP2025175052A5 publication Critical patent/JP2025175052A5/ja
Pending legal-status Critical Current

Links

JP2025147778A 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤 Pending JP2025175052A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962916942P 2019-10-18 2019-10-18
US62/916,942 2019-10-18
JP2022523023A JP7744687B2 (ja) 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤
PCT/US2020/056255 WO2021077067A1 (en) 2019-10-18 2020-10-19 Lipid nanoparticles and formulations thereof for car mrna delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022523023A Division JP7744687B2 (ja) 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤

Publications (2)

Publication Number Publication Date
JP2025175052A JP2025175052A (ja) 2025-11-28
JP2025175052A5 true JP2025175052A5 (cg-RX-API-DMAC7.html) 2026-01-22

Family

ID=75538674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523023A Active JP7744687B2 (ja) 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤
JP2025147778A Pending JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022523023A Active JP7744687B2 (ja) 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤

Country Status (8)

Country Link
US (1) US20220378700A1 (cg-RX-API-DMAC7.html)
EP (1) EP4045021A4 (cg-RX-API-DMAC7.html)
JP (2) JP7744687B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220084366A (cg-RX-API-DMAC7.html)
CN (1) CN114828837A (cg-RX-API-DMAC7.html)
AU (1) AU2020366519B2 (cg-RX-API-DMAC7.html)
CA (1) CA3155075A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021077067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
US20240298649A1 (en) * 2021-06-14 2024-09-12 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN115724806B (zh) * 2021-08-25 2025-07-01 广州谷森制药有限公司 阳离子脂质化合物
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CA3233490A1 (en) * 2021-09-28 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents
EP4408437A4 (en) * 2021-10-01 2025-08-27 Univ Pennsylvania LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183300A1 (en) * 2022-03-22 2023-09-28 The Children's Medical Center Corporation Compositions and methods for prevention and treatment of genetic disease
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
EP4519243A4 (en) * 2022-05-04 2026-04-22 Univ Pennsylvania Siloxane-based lipids, lipid nanoparticle compositions comprising them, and their methods of use for targeted administration
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
WO2024026029A2 (en) * 2022-07-27 2024-02-01 Trustees Of Tufts College Lipid nanoparticles for immunotherapy
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024206230A1 (en) * 2023-03-24 2024-10-03 Trustees Of Tufts College Tissue targeting lipids and lipid nanoparticles
WO2024220609A1 (en) * 2023-04-18 2024-10-24 The Trustees Of The University Of Pennsylvania Ionizable lipid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof for cell engineering
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025008510A1 (en) * 2023-07-06 2025-01-09 Etherna Immunotherapies Nv Ionizable lipids
IT202300015003A1 (it) * 2023-07-18 2025-01-18 Univ Degli Studi Di Salerno Composizione e procedimento per la realizzazione di nano-carriers lipidici ed i relativi nano-carriers lipidici di uso biomedico
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
EP4771154A2 (en) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
EP4784174A1 (en) * 2023-09-28 2026-08-05 Trustees of the University of Pennsylvania Compositions and methods for targeting immune cells
WO2025075396A1 (ko) * 2023-10-06 2025-04-10 한국과학기술연구원 타겟 핵산 검출물질이 담지된 지질 나노입자 및 이를 이용한 막융합 기반의 타겟 핵산 검출 방법
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
IL327927A (en) * 2023-10-22 2026-06-01 Tessera Therapeutics Inc Lipid nanoparticles for delivery of therapeutic payloads to t cells
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
AU2024409393A1 (en) * 2023-12-18 2026-07-09 Nanovation Therapeutics Inc. Lipid nanoparticles having non-polar lipids for nucleic acid delivery to the liver
AU2024409925A1 (en) 2023-12-26 2026-08-06 Emmune, Inc. Systems for nucleic acid transfer
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025184476A1 (en) * 2024-02-29 2025-09-04 The Trustees Of The University Of Pennsylvania Cationic degradable lipid compositions, lipid nanoparticles (lnps) comprising same, and methods of use thereof
WO2025252759A1 (en) 2024-06-03 2025-12-11 Bio-Sourcing Transient expression by lipid nanoparticle formulations
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026015458A1 (en) * 2024-07-08 2026-01-15 Memorial Sloan-Kettering Cancer Center Cells comprising non-hla restricted t cell receptors
WO2026071602A1 (ko) * 2024-09-30 2026-04-02 한국과학기술연구원 면역세포 내 유전자 조작을 위한 신규한 지질나노입자 조성물
WO2026095067A1 (ja) * 2024-11-01 2026-05-07 Agc株式会社 核酸送達用脂質ナノ粒子
WO2026109722A1 (en) 2024-11-21 2026-05-28 Aldexchem Kft. Advanced silicon-containing lipid nanoparticles for efficient human t cell transfection
WO2026122685A1 (en) 2024-12-03 2026-06-11 Orna Therapeutics, Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026161895A1 (en) 2025-01-27 2026-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression
WO2026165530A1 (en) 2025-02-03 2026-08-06 Renagade Therapeutics Management Inc. Hydrophilic polymer lipids for use in lipid nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053572A2 (en) * 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9126966B2 (en) * 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
EP3247328B1 (en) * 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
AU2017337073A1 (en) * 2016-09-30 2019-04-18 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
US20190314291A1 (en) * 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Similar Documents

Publication Publication Date Title
JP2026012402A5 (cg-RX-API-DMAC7.html)
JP2022552008A5 (cg-RX-API-DMAC7.html)
JP2022552009A5 (cg-RX-API-DMAC7.html)
US20230165973A1 (en) Compositions and methods for delivering messenger rna
JP2021535227A5 (cg-RX-API-DMAC7.html)
Liu et al. mRNA cancer vaccines: construction and boosting strategies
JP5977394B2 (ja) 脂質に封入された干渉rna
US20200016274A1 (en) Messenger rna vaccines and uses thereof
JP2021535226A5 (cg-RX-API-DMAC7.html)
US20250381140A1 (en) Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery
JP2022511977A (ja) KRASバリアントmRNA分子
US20180245074A1 (en) Treating hepatitis b virus infection using crispr
US12485170B2 (en) Lipid composition targeting antigen-presenting cells and use thereof
CN1981044A (zh) 包封干扰rna的脂质
US20250325490A1 (en) Lipid compound, lipid nanoparticle comprising same and use thereof
WO2023144792A1 (en) Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
RU2476204C2 (ru) Носитель лекарственного средства
JP2005513073A6 (ja) ポリヌクレオチドを細胞へトランスフェクションするための組成物の製造のためのリゾ脂質の使用
WO2024216243A2 (en) Peptide-based vaccines and methods for treatment
JP2002533354A (ja) 安定なポジプレックスの懸濁液の製造法
WO2026020403A1 (en) Ionizable lipid derived from alkyl substituted 1, 4, 7-triazacyclononane or 1, 4, 7, 10-tetraazacyclododecane, compositions and uses thereof
BR102025005957A2 (pt) Composição lipídica, uso de uma composição lipídica, composição, método de preparação de uma composição para a administração de um agente terapêutico e/ou profilático às células que apresentam antígenos em órgãos alvo e uso
CN109913455B (zh) 一种能够治疗癌症的小干扰rna
EA050406B1 (ru) Катионные липиды, содержащие кремний
Elnaggar et al. Delivery of Rna Drugs: Beyond the Liver, More than Vaccine